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ABSTRACT 
The ability to alter the genes of future generations no longer 
belongs in the realm of science fiction. The genetic modification 
capabilities of modern science are advancing rapidly. 
Mitochondrial replacement therapy (MRT) represents the first 
crossing of the germline barrier in humans, and as of February 
2015, it is the first procedure of its kind to be legalized in the 
Western world. How Congress decides to regulate MRT will 
influence future regulation of all genetic manipulation 
technologies. This brief argues that the current patchwork 
regulatory framework established in the United States is 
insufficient to deal with the complex issues MRT presents. As such, 
the creation of a new regulatory agency specifically focused on the 
oversight of reproductive and genetic biotechnologies may be 
necessary to balance the goals of ensuring the safety of research 
participants, promoting public debate, and stimulating continued 
scientific progress.  
INTRODUCTION 
 The field of reproductive technology is renowned for pushing 
boundaries and contributing innovative approaches to the pursuit of fertility 
enhancement. In vitro fertilization (IVF), for example, was “recognized by a 
Nobel Prize in physiology and medicine . . . [which] all but vanquished the 
scourge of infertility.”1  Yet, with the convergence of reproductive sciences 
and genetic technologies, IVF is on its way to being supplanted by 
unprecedented breakthroughs that will transform reproductive medicine as 
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1 Eli Y. Adashi, Fifty Years After Huxley: The Roadmap of Reproductive Medicine 
Revisited and Updated: The 2015 SRI-Pardi Distinguished Scientist Plenary 
Lecture of the Society of Reproductive Investigation, 22 REPROD. SCI. 1330, 1330 
(2015).  
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we know it.2 These breakthroughs involve germline modification, a form of 
human genetic engineering that aims to alter the genes in sperm, eggs cells 
or embryos.3 Unlike somatic modifications,4 where changes in the genetic 
makeup die with their bearer, germline modifications affect every cell in the 
body, not only in the children that result from the procedure, but in all 
succeeding generations.5  
 In the face of such historic developments in our scientific 
capabilities, legislators must reexamine how to regulate the development 
and use of these innovations in the United States. This brief focuses on 
mitochondrial replacement therapy (MRT), which some deem a test case 
for the regulation of germline modification procedures.6 MRT is a technique 
that prevents a host of severe neurological disorders caused by mutant 
mitochondrial DNA (mtDNA) by replacing it with healthy mtDNA 
extracted from donated eggs.7 Because the changes are heritable, this 
procedure is a form of germline engineering. Although the technology has 
faced both praise and controversy,8 the development of MRT is undeniably 
historic9: 
First, MRT represents the first ever crossing of the germline barrier. 
Second, MRT constitutes the first ever form of organelle, indeed 
whole cytoplasmic replacement therapy. Third, MRT represents the 
first ever gene therapy that is IVF based. Fourth, MRT serves as a 
regulatory test case for all future cutting-edge reproductive 
technologies. Fifth, MRT irrevocably alters the face of assisted 
reproduction from a discipline focused on infertility to one with a far 
broader portfolio.10 
                                                     
2 See id.  
3 See Human Cloning and Genetic Modification: The Basic Science You Need To 
Know, ASS’N OF REPROD. HEALTH PROF’LS 5, http://www.arhp.org/upload 
Docs/cloning.pdf. (last visited Nov. 23, 2015) [hereinafter, Ass’n of Reprod. 
Health].  
4 Id. (“‘Somatic’ genetic engineering is genetic engineering that targets the genes in 
specific organs and tissues of the body of a single existing person without affecting 
genes in their eggs or sperm.”). 
5 Id. 
6 Adashi, supra note 1, at 1332. 
7 Ruth L. Fischbach, Shawna Benston & John D. Loike, Creating a Three-Parent 
Child: An Educational Paradigm for the Responsible Conduct of Research, 15 J. 
MICROBIO. & BIO. EDUC. 186, 186 (2014). 
8 See Gretchen Vogel & Erik Stokstad, U.K. Parliament Approves Controversial 
Three-Parent Mitochondrial Gene Therapy, SCIENCE (Feb. 3, 2015, 2:00 PM), 
http://news.sciencemag.org/biology/2015/02/u-k-parliament-approves-
controversial-three-parent-mitochondrial-gene-therapy. 
9 See Adashi, supra note 1, at 1332.  
10 Id.  
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 This brief argues that the patchwork regulatory framework currently 
established in the United States is insufficient to deal with the complex 
issues at play. Instead, Congress should create a new regulatory agency to 
focus on the oversight of reproductive and genetic biotechnologies. 
I. THE SCIENCE BEHIND MITOCHONDRIAL REPLACEMENT THERAPY 
 Our bodies are formed from a collection of cells, each containing 
forty-six chromosomes—tightly-packed groups of DNA that provide the 
blueprint for our development and functioning.11 Each cell contains a 
nucleus that houses almost all our genetic material, and a mitochondrion, 
which acts as the cell’s battery pack, using oxygen to create energy that 
powers the cell.12 The mitochondrion also contains a small amount of its 
own genetic material, called mitochondrial DNA (mtDNA).13 In 
reproduction, the egg and the sperm each carry half of the required number 
of chromosomes and combine their nuclear DNA to create a zygote, which 
divides to form an embryo.14 mtDNA, however, is unique in that it is not 
created by a combination of its parents’ cell DNA.15 Instead, individuals 
inherit mtDNA exclusively from their mothers.16  
 Although mtDNA accounts for a very small percentage of the 
human genome, mitochondrial gene mutations can cause severe 
neurological consequences.17 Mutant mtDNA “gives rise to a broad range of 
inborn errors of energy metabolism, the manifestations of which are highly 
disabling and often fatal.”18 More devastatingly, because mtDNA is passed 
on from the egg, all children from affected women inherit these 
mitochondrial mutations.19 
 MRT is a new fertility treatment that could prevent genetic diseases 
that stem from mutant mtDNA. The procedure works by removing the 
nuclear DNA from the target egg’s defective mtDNA and placing it within a 
                                                     
11 J. Ravindra Fernando, Note, Three’s Company: A Constitutional Analysis of 
Prohibiting Access to Three-Parent In Vitro Fertilization, 29 NOTRE DAME J. L. 
ETHICS & PUB POL’Y 523, 528 (2015).  
12 Id. 
13 Fischbach et al., supra note 7, at 187 (“Human beings have approximately 20,000 
genes in their nuclear chromosomes and only about 35 genes in their 
mitochondria.”). 
14 ASS’N OF REPROD. HEALTH, supra note 3, at 2.  
15 See Fischbach et al., supra note 7, at 187 (explaining that the mitochondria is 
located on the tail section of a sperm cell, which is broken off and excluded once 
the head portion, containing the nuclear DNA, successfully enters the egg). 
16 Fernando, supra note 11, at 529. 
17 Fischbach et al., supra note 7, at 186.  
18 Adashi, supra note 1, at 1331. 
19 Fischbach et al., supra note 7, at 186. 
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donated egg with healthy mtDNA.20 The nuclear DNA of the donated egg is 
similarly removed so that the healthy mtDNA is the only contribution by 
the donor.21 The need for MRT is apparent for families carrying mtDNA. 
While the treatment does little to help those currently living with 
mitochondrial disease, it allows the second generation transmission of 
mtDNA-based diseases to be circumvented.22 For families carrying mtDNA, 
MRT is a source of hope for a future with genetically related children.  
II.   CONSIDERATIONS FOR SELECTING A REGULATORY FRAMEWORK 
FOR GERMLINE MODIFICATIONS IN THE UNITED STATES 
A.  MRT as a Regulatory Test Case 
 The significance of the resulting germline modification in MRT is 
small since mtDNA only “represents less than 0.2% of the total human 
genome.”23 The potential and perils of germline modification can be seen 
more vividly in other rapidly developing technologies such as ZFN, 
TALEN, CRISPR-Cas9 and ARCUS, which provide the ability to induce 
site-specific DNA changes in the genome.24 However, this paper focuses on 
MRT as the regulatory test case for all future reproductive genetic 
technologies because a discussion of the regulatory regime behind MRT is 
both more relevant and salient. MRT represents the first ever crossing of the 
germline barrier in humans, and is the first procedure of its kind to be 
legalized in the Western world.25 
 In February 2015, both the House of Commons and the House of 
Lords in the United Kingdom overwhelmingly approved the use of MRT in 
humans,26 making it the first country in the world to allow mitochondrial 
replacement therapy.27 It has been noted that “[t]he regulatory adjudication 
of MRT in the United Kingdom, several years in the making, was 
exemplary in its focus on safety, ethics, and public receptivity.”28 With 
                                                     
20 Don P. Wolf, Nargiz Mitalipov & Shoukhrat Mitalipov, Mitochondrial 
Replacement Therapy in Reproductive Medicine, 21 TRENDS IN MOLECULAR MED. 
68, 68-69 (2015).  
21 Id.  
22 See id.  
23 Fischbach et al., supra note 7, at 186. 
24 Hyongbum Kim & Jin-Soo Kim, A Guide to Genome Engineering with 
Programmable Nucleases, 15 NATURE REVS. GENETICS 321, 321 (2014).  
25 See Vogel & Stokstad, supra note 8.  
26 Adashi, supra note 1, at 1331. 
27 See Kashmira Gander, World’s First Three-Parent Baby Could Soon Be Born in 
UK, as Government Approves Treatment, INDEPENDENT, Jul. 22, 2014,  
http://www.independent.co.uk/news/science/worlds-first-three-parent-baby-could-
soon-be-born-in-uk-as-government-approves-treatment-9621572.html. 
28 Adashi, supra note 1, at 1331. 
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precedent set by the international community, and escalating pressure from 
within the country,29 Congress must soon decide whether and how to 
regulate reproductive genetic technologies. Thus, Congress’s treatment of 
MRT may lay the foundation for how advances in this field will be dealt 
with in the future.  
B.  Framing the Options and Criteria 
 For germline modification technologies like MRT, currently no 
“federal or state legislation specifically governs this advanced reproductive 
technology” in the United States.30  
 In this context, there are several regulatory pathways that may be 
adopted to provide oversight for germline modification technologies.  
1. Maintain the Status Quo: The regulation of germline 
modification technology may be left to be regulated by 
market forces in the private sector. 
2. Cede Authority to the FDA: Authority to regulate 
germline modification technologies may be granted to 
the FDA. 
3. Create a New Independent Regulatory Agency: 
Congress could enact legislation authorizing the 
creation of a new regulatory agency focused 
specifically on the oversight reproductive and genetic 
biotechnologies. 
 If the regulatory treatment of MRT is to serve as a foundation for 
the regulation of future germline modification technologies, each of the 
possible alternatives available to Congress must be compared and tested. 
Although there may be a variety of relevant and important goals, this brief 
will focus on the ability of a regulatory framework to: 
• Maximize safety and well-being for research 
participants. 
• Encourage full and open debate. 
• Ensure and enable the continued advancement of 
scientific progress.  
The following sections will consider each of the presented regulatory 
alternatives individually against these three criteria.  
                                                     
29 Fernando, supra note 11, at 527. 
30 Id. at 526.  
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III.   OPTION ONE: MAINTAINING THE STATUS QUO 
 The United States currently employs a patchwork system of 
oversight for reproductive genetic technologies.31 There are “no federal 
law[s] or promulgated regulations directly addressing the genetic 
modification of gametes or early embryos” in humans.32 Various aspects of 
reproductive research are covered by certain state laws.33 Although without 
any formal regulatory authority, several NGOs and professional 
organizations in reproductive medicine have also set practice standards.34 
The only source of federal oversight comes from from the National Institute 
of Health (NIH) and the Food and Drug Administration (FDA).35 The role 
of both these institutions in regulating reproductive technologies like MRT 
is both limited and uncertain. 
 The NIH, for example, considers the “social and ethical 
implications of ‘novel gene-transfer research protocols,’” through the 
Recombinant DNA Advisory Committee (RAC).36  However, RAC’s 
mandate is limited to technology present in the 1980s, and thus, “it 
considers only those interventions that involve recombinant DNA.”37 As a 
result, because MRT involves cellular surgery rather than recombinant 
DNA, it technically falls outside the RAC’s purview despite the fact that 
inheritable genetic modifications are involved.38 Regardless, as a matter of 
policy, the RAC has stated that it will not review any proposals that involve 
the modification of gametes or embryos.39 By refusing to review proposals, 
the RAC effectively cut off federal funding for germline modification 
research. In April 2015, the NIH more explicitly affirmed that heritable 
genetic modifications fall under the Dickey-Wicker Amendment, meaning 
that no federal funds will be made available for such research.40 As a result 
of the current patchwork framework, the advancement and regulation of 
germline modification technology has essentially been left to market forces 
and the private sector.  
 The first option, and likely the easiest, is to maintain the status quo, 
leaving regulation to free-market forces. Several writers have suggested 
                                                     
31 Erik Parens & Lori P. Knowles, Reprogenetics and Public Policy: Reflections 
and Recommendations, 33 HASTINGS CTR. REP. S1, S10 (2003). 
32 Girard Kelly, Comment, Choosing the Genetics of Our Children: Options for 
Framing Public Policy, 30 SANTA CLARA HIGH TECH. L.J. 303, 336 (2014). 
33 Parens & Knowles, supra note 31, at S12.  
34 Kelly, supra note 32, at 336–339. 
35 Fernando, supra note 11, at 526–27. 
36 Kelly, supra note 32, at 337.  
37 Parens & Knowles, supra note 31, at S11.  
38 See id. 
39 Kelly, supra note 32, at 337. 
40 Editorial, Gene Politics, 523 NATURE 5, 6 (2015). 
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that, if left to the market, “most regulation will occur informally through the 
market interactions of willing consumers and providers of these services 
against a background of common law norms, some professional self-
regulation, and occasional state legislative intrusions.”41 However, this 
patchwork approach is insufficient because it fails to adequately ensure 
safety and well-being, full and open public debate, and promote scientific 
progress.  
A.  The Private Sector and Safety & Well-Being 
 To leave the regulation of reproductive genetic research to the 
private sector may be dangerous for research participants and would place 
the United States in stark contrast with the approach taken by the rest of the 
world.42 In the context of gene therapies, for example, researchers and 
clinicians have expressed concern that risks are taken in the private sector 
with little understanding of the long-term health consequences.43 
Unfortunately, experimental reproductive techniques have been rapidly 
introduced on the market “without sufficient prior animal experimentation, 
randomized clinical trials, or the rigorous data collection that would occur 
in federally funded studies.”44 As summarized by the National Conference 
of State Legislatures, “a substantial proportion of research and innovative 
therapy in reproductive medicine need not be subject to peer review, may 
not conform to current standards for informed consent, and may be offering 
services that have never been fully evaluated for safety and efficiency.”45 
Germline modification technologies are rife with potential dangers, risks 
that have radical implications for the well-being of future generations. Such 
a technology demands a public system of oversight that “relies on more than 
the discretion of individual researchers and their institutions.”46  
B.  The Private Sector and Public Debate 
 In addition to issues of participant safety, allowing the bulk of 
germline modification research to remain in the private sector is also 
“incompatible with the ideal of conducting such work in the light of 
forthright public deliberation.”47 The modification of heritable genes raises 
deep ethical questions and complex considerations regarding the well-being 
of families and society. The consequences of any side effects of such 
                                                     
41 See John A. Robertson, Procreative Liberty in the Era of Genomics, 29 AM. J.L. 
& MED. 439, 483–84 (2003). 
42 Parens & Knowles, supra note 31, at S11.  
43 Id. 
44 Id.  
45 Id. 
46 Id. 
47 Id. at S10.  
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treatment may not be foreseeable or expressed until years into the child’s 
life or perhaps generations down the line. In addition to the risks of these 
procedures to subsequent generations, innumerable challenging questions 
arise that cannot be fully answered by science. What sort of procedures do 
we consider moral? How do we deal with other countries with different 
values and should we be concerned about keeping up with the technological 
advancements of other nations? How do you respect the autonomy of those 
who consent and willingly engage in such research despite the risks and can 
parents’ consent on behalf of their unborn children?48 How do we ensure 
equal access to such technology and avoid situations of exploitation and 
social injustice?49 How do we address concerns regarding the potential rise 
of designer babies and eugenics?50  
 We, as a society, must decide what risks we are willing to accept 
and where we draw the line. “[S]ince scientists are members of a 
democratic community who share resources (and all researchers in this 
country benefit directly or indirectly from our extraordinary scientific 
infrastructure), they are obliged to subject their research to public 
scrutiny.”51 A decision as important as whether to allow inheritable genetic 
modification should not be left to individual researchers and the private 
sector.  
C.  The Private Sector and Scientific Progress 
 Finally, the natural secrecy of the private sector may impede the 
progression of germline modification research.52 Without public funding, 
research and innovation will remain in the hands of the private industry, 
who have no incentive to share the fruits of their labor. With the potential 
that germline modification technologies hold for saving lives and curing a 
host of genetic diseases, public research in this field should be promoted. 
Some will argue that the financial incentives of an unregulated free-market 
will result in the most technological advancement. However, incentives to 
cut corners and accept greater risks in the private sector may eliminate the 
therapeutic and financial rewards of germline modifications. Jesse 
Gelsinger is a vivid example.  
 Jesse Gelsinger suffered from ornithine transcarbamylase 
deficiency (OTC), a rare metabolic disorder that prevented the body from 
                                                     
48 See Joanna Smolenski, CRISPR/Cas9 and Germline Modification: New 
Difficulties in Obtaining Informed Consent, 15 AM. J. BIOETHICS 35, 35-68 (2015).   
49 See Parens & Knowles, supra note 31, at S7. 
50 Id. 
51Id. at S11. 
52 See id. at S10.  
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breaking down ammonia.53  He died in 1999 during a gene-therapy 
experiment gone wrong at the University of Pennsylvania.54 In the 1990s, 
the ability of gene therapy “to cure was thought to be boundless and the 
hype was astronomical” as companies invested millions of dollars in the 
technology.55 Yet, after a series of revelations regarding serious deficiencies 
in informed consent and study design, progress in gene therapy stalled as 
public opinion and trust collapsed. “Gene therapy remains an obvious route 
to treat OTC . . . [b]ut the memory of what happened to Gelsinger has 
slowed progress in gene therapy for any condition.”56 
 Just like pharmaceutical and the biotech industries, clinical trials are 
the lifeblood of reproductive technologies. Profit driven motives to cut 
corners on informed consent and safety precautions in order to access 
human test subjects increases the likelihood of tragedies such as Jesse 
Gelsinger. Contrary to the financial interests of the private sector, avoidable 
failures could stymie research in germline modification for decades. In 
order to promote technological advancement, and to unlock both the 
financial and therapeutic potential it offers, more robust and regulated 
safety precautions must be put in place to protect the “fragile nature of the 
public trust that sustains research.”57 
IV.   OPTION TWO: THE FOOD AND DRUG ADMINISTRATION 
 The authority to regulate germline modification technologies could 
be ceded to the FDA. The FDA has already asserted its jurisdiction over 
MRT through the Office of Cellular, Tissue, and Gene Therapies of the 
Center for Biologics Evaluation and Research.58 This branch of the FDA’s 
task is to oversee “human cells used in therapy involving the transfer of 
genetic material by means other than the union of gamete nuclei.”59 The 
FDA’s claim to MRT rests upon the therapy’s inclusion under the broad 
definition of a “drug.”60 A “drug” is defined by the Food, Drug, and 
                                                     
53 Osagie K. Obasogie, Ten Years Later: Jesse Gelsinger’s Death and Human 
Subjects Protection, THE HASTINGS CENTER: BLOG (Oct. 22 2009), http://www. 
thehastingscenter.org/ten-years-later-jesse-gelsingers-death-and-human-subjects-
protection.  
54 Id.  
55 Id.  
56 See Editorial, Gene-Therapy Trials Must Proceed with Caution, 534 NATURE 
590, 590 (2016). 
57 Mark Yarborough & Richard R. Sharp, Public Trust and Research a Decade 
Later: What Have We Learned Since Jesse Gelsinger’s Death?, 97 MOLECULAR 
GENETICS & METABOLISM 4, 4 (2009).  
58 Glenn Cohen, Julian Savulescu & Eli Y. Adashi, Transatlantic Lessons in 
Regulation of Mitochondrial Replacement Therapy, 348 SCI. 178, 179 (2015). 
59 Id. 
60 Kelly, supra note 32, at 342. 
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Cosmetic Act to encompass anything that is “intended for use in the 
diagnosis, cure, mitigation, treatment, or prevention of disease,” or that is 
“intended to affect the structure or any function of the body.”61 Although 
this option can ensure the safety and efficacy of research participants, 
ceding authority to the FDA may not be the best option as it falls short in its 
ability to consider well-being, promote public debate, and ensure continued 
scientific progress.  
A.  The FDA and Safety & Well-Being 
 The advantage for ceding authority to the FDA is that it already 
exists and it is arguably ready to exercise oversight, at least on safety and 
efficacy grounds. Under the FDA’s existing regulations, approval of MRT 
for therapeutic use will require “phased clinical trials pursuant to an 
Investigational New Drug application (IND).”62 To gain the FDA’s 
approval, the technology will be subject to a “searching review of the 
method’s safety and efficacy as well as satisfactory completion of human 
trials.”63 Thus, regulation of MRT by the FDA would provide significantly 
more comprehensive oversight in ensuring the safety of research 
participants.  
 On the other hand, because the FDA’s mandate is limited to issues 
related to safety and efficacy, considerations regarding the “well-being” of 
the research participants and of society will be neglected under the FDA’s 
authority.64 As discussed above, this is significant because the modification 
of heritable genes raises deep ethical questions and considerations regarding 
the well-being of families and society. For example, germline modification 
techniques such as MRT permanently change the mtDNA in every cell of 
the resulting child,65 unlike normal drugs where the doses can be slowly 
increased and stopped in the event of a serious side effect. The 
consequences of any side effects may not be foreseeable or expressed until 
years into the child’s life. As such, classifying MRT as “drugs likely 
encompasses too broad of a definition and offers inadequate regulation for a 
drug that would change the structure and function of the human body.”66 It 
would be best if technologies like MRT did not fall exclusively within 
FDA’s mandate.67 
                                                     
61 Id. at 342-43. 
62 Id. at 337–38. 
63 Fernando, supra note 11, at 526–27. 
64 Kelly, supra note 32, at 345–46. 
65 See ASS’N OF REPROD. HEALTH, supra note 3, at *5. 
66 Kelly, supra note 32, at 343. 
67 Parens & Knowles, supra note 31, at S12.  
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 Congress may choose to remedy this by endowing the FDA with 
the power to consider moral and philosophical issues of the technology.68 
To do so will require Congress to expand the FDA’s regulatory authority 
without distorting its current three-tier classifications.69 Such a radical 
change would require reorganization of the agency and its members.70 With 
the complexity and expenses related to such reorganization in mind, it 
would make more sense for Congress to focus its resources on creating a 
new independent agency and framework for oversight.71 
B.  The FDA and Public Debate 
 Due to the complex and controversial nature of genetic 
modification, decisions regarding germline modification should be informed 
by collaborative public discussions on both safety and well-being 
concerns.72 In this respect, the FDA is also severely lacking. In the United 
States, discussions regarding MRT have been limited to a few conversations 
among experts, with relatively little input from the public.73 In fact, the 
FDA has never officially even considered clinical trials for MRT. The only 
time it was discussed was in early 2014 during a discussion regarding 
“oocyte modification” by the FDA’s Cellular, Tissue, and Gene Therapies 
Advisory Committee.74 No official conclusion from the meeting was ever 
provided and the results were merely summarized by the chairman with the 
brief comment that “[s]everal panelists felt ‘there was probably not enough 
data in animals . . . to move on to human trials without answering a few 
additional questions.’”75 The FDA has also commissioned the committee of 
the Institute of Medicine to provide an ad hoc review of the ethical and 
social considerations of novel approaches to treating mitochondrial DNA 
diseases.76 However, “only two of the planned committee sessions will be 
available to the public.”77 
                                                     
68 Kelly, supra note 32, at 345–46. 
69 See id. at 344–46. 
70 Id. 
71 Id.  
72 See Mark S. Frankel and Audrey R. Chapman, Human Inheritable Modifications: 
Assessing Scientific, Ethical, Religious, and Policy Issues, AM. ASS’N FOR THE 
ADVANCEMENT OF SCI., Sept. 2002, at 3–5, https://www.aaas. 
org/sites/default/files/migrate/uploads/germline.pdf. 
73 Cohen et al., supra note 58, at 179. 
74 Id.  
75 Id.; see also Sharon Begley, U.S. FDA Weighs Evidence on Producing ‘Three-
Parent’ Embryos, REUTERS (Feb. 25, 2014), http://www.reuters.com/article/us-usa-
health-ivf-idUSBREA1O1WL20140225. 
76 Cohen et al., supra note 58, at 179.  
77 Id. 
132 MITOCHONDRIAL REPLACEMENT THERAPY [Vol. 15 
C.  The FDA and Scientific Progress 
 Finally, the FDA’s recent actions have done little to create 
confidence in its ability to foster safe but productive research in this field. 
As mentioned, MRT was largely ignored in a brief discussion by the FDA’s 
Cellular, Tissue, and Gene Therapies Advisory Committee in 2014.78 No 
further FDA action is expected until the Institute of Medicine report has 
been released, which is estimated to be around early 2016.79 Meanwhile, 
“any relevant INDs submitted would remain on hold.”80  
 In terms of the goal of promoting scientific progress, the FDA is not 
the ideal option for regulating germline modifications because it is not 
efficiently structured to deal with novel fields that are developing as rapidly 
as reproductive genetics. This stems from the fact that the FDA’s mandate 
is both too broad and too narrow. The FDA’s authority is too broad because 
it encompasses all therapeutics. For example, even the FDA Office of 
Cellular, Tissue, and Gene Therapies—the designated proximate overseer of 
MRT—is entrusted with a diverse portfolio of cellular, tissue, and gene 
therapeutics. 81 On the other hand, FDA’s authority is too narrow for it 
extends only to (i) drugs, (ii) biologics and (iii) and devices.82 Thus, the 
FDA must proceed on the premise that MRT constitutes a drug or a 
biological product.83 In other words, novel scientific advances must be 
manipulated and jerry-rigged to fit the FDA’s current and outdated three-
category framework. The necessity of having to classify every potential 
genetic engineering technology as a drug, biologic, or device is a regulatory 
challenge and creates an environment of uncertainty. The resulting 
confusion may have a chilling effect among scientists and investors who 
shy away from potential breakthroughs due to the unpredictability of 
whether the FDA will exert jurisdiction over new technologies and under 
which category it will be classified. By stunting investment and critical 
scientific research, the U.S. risks losing its edge and its market share to 
areas with more fluid and predictable regulations such as the UK.84  
                                                     
78 Id. 
79 Id. 
80 Id. 
81 Kelly, supra note 32, at 342. 
82 See id. at 342–43.  
83 Id. 
84 See Christopher J.P. Velis, Ambiguity from FDA Stunts Growth in the US, While 
Innovation Flourishes in Europe, REG. AFF. PROF. SOC’Y (Jul. 23, 2013), 
http://www.raps.org/Regulatory-Focus/Features/Transfered-Features/2013/07/ 
23/9202/Ambiguity-from-FDA-Stunts-Growth-in-the-US-While-Innovation-
Flourishes-in-Europe/. 
No. 1] DUKE LAW & TECHNOLOGY REVIEW 133 
V. OPTION THREE: A NEW INDEPENDENT REGULATORY AGENCY 
 Congress could enact legislation authorizing the creation of a new 
regulatory agency focused specifically on the oversight of reproductive and 
genetic biotechnologies. This would be comparable to agencies that exist in 
other countries such as the Assisted Human Reproduction Agency (AHRA) 
in Canada and the Human Fertilisation and Embryology Authority (HFEA) 
in the United Kingdom.85  
 The creation of an independent agency addresses many of the 
shortcomings of the current patchwork regulation in the U.S. and of ceding 
oversight authority to the FDA. Thus, it may be the best option to maximize 
the safety and well-being of research participants, promote public debate, 
and ensure the continued advancement of scientific progress in the United 
States. The recent “exemplary” success of the “regulatory adjudication of 
MRT” by the HFEA is illustrative of the capacities of an independent 
agency.86 The UK regulatory experience may also provide invaluable 
insight into how a similar agency in the United States could be structured. 
A.  The New Agency and Safety & Well-Being 
 First, the creation of an independent regulatory agency will better 
maximize the safety and well-being of research participants. An agency 
tasked with the responsibilities and regulatory authority of an IRB would be 
able to adequately perform scientific and ethical reviews of all germline 
research protocols and procedures.87 In addition, the “new agency could be 
authorized to directly consider policy concerns that extend beyond the 
FDA’s purview of safety and efficacy.”88 By appointing individuals with 
more specialized expertise, a new agency will be more competent than the 
FDA in dealing with the complex array of social, ethical, and legal issues 
implicated by germline modifications.89  
 The success of such an independent regulatory agency has been 
demonstrated by the HFEA in the United Kingdom. The HFEA is 
responsible “for licensing and monitoring clinics and laboratories involved 
in gamete or embryo storage, creation, or use, and the act sets out the 
purposes for which licenses will be required . . . .”90 The HFEA establishes 
and publishes a code of practice that acts as a source of guidance for 
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patients, clinics, and clinicians as to the proper conduct of actions carried on 
under a HFEA license.91 “Through the setting of standards and the provision 
of licenses, the HFEA provides both quality control and assurances that 
ethical conduct in embryo research is maintained.”92 If the U.S. creates a 
similar independent agency with the ability to oversee germline research 
and clinical application at a federal level, the government will be able to 
better ensure both scientific quality assurance and greater certainty that 
ethically unacceptable activities will not be conducted behind the closed 
doors of the private sector. 
B.  The New Agency and Public Debate 
 The limited interaction between private institutions and the FDA 
with the public stands in stark contrast to what can be accomplished by an 
independent regulatory agency. For example, the difference between the 
relative weight assigned to public consultation on regulatory issues by the 
FDA and the HFEA is staggering. In the UK, the “public consultation 
process was an extensive outsourced multimethod (e.g., surveys and 
workshops) effort on a national scale lasting 6 months,”93 and has been 
praised to be “nothing short of exemplary in its focus on safety, ethics, and 
public receptivity.”94 The vetting process in the United States, on the other 
hand, has been described as “a work in progress.”95 
 The flexibility provided by the creation of a new independent 
regulatory agency can be used to establish a system that can foster the 
discussion of safety and well-being concerns with the greater public. This is 
particularly important in the United States, where the lack of uniform 
oversight for reproductive technologies can be partially attributed to the 
deep and divisive debate around the issue of abortion.96 In the backdrop of 
the polarizing and volatile dynamics of this debate, many policymakers 
have been reluctant to join the conversation, which has greatly hampered 
the regulation and advancement of assisted reproductive technologies.97   
 If reproductive genetic research is to be taken seriously, both sides 
must begin to join the conversation and find way to compromise. 
Discussions regarding MRT can no longer be isolated to select experts in 
the FDA or relegated to individual researchers and their private financial 
backers. A new independent agency separate from the political arena with a 
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diverse board along the lines of the HFEA will help ensure that the concerns 
of both sides of the abortion debate are taken seriously.98 Members of the 
board may be appointed by a bipartisan committee, with representation 
from all of the stakeholders involved.99 Such an independent agency will 
allow engagement with the public, increase understanding, and build 
consensus among traditionally hostile groups. 
C.  The New Agency and Scientific Progress 
 Despite the traditional belief that more regulations result in greater 
restrictions on innovation, a new regulatory agency would likely accelerate 
future research and development of reproductive genetic technologies. 
Several lessons can be drawn from the UK regulatory paradigm regarding 
the continued progress of scientific advancement. Clinical trials in the UK 
began as early as October 2015, whereas the FDA has essentially put a stop 
to all MRT research in the United States.100 
1. Specialized and Expert Nature 
 First, the HFEA is a specialized agency whose sole charge is to 
regulate reproductive technologies.101 Thus, the HFEA was more capable 
and expert in their treatment of MRT, which was viewed “as a 
circumscribed outgrowth of related and highly familiar technologies (e.g., in 
vitro fertilization) rather than as a therapeutic.” 102  
 The creation of a new independent agency in the United States 
would allow the appointment of individuals with more specialized expertise 
who will be more competent than the FDA in dealing with the complex 
array of social, ethical, and legal issues implicated by germline modification 
technologies.103  Further, germline modification research would no longer 
need to be manipulated and interpreted to fit into the FDA’s existing three-
category framework. 
2. Ability to Foster National Pride 
 Second, MRT research was a tremendous source of pride in the 
UK.104 “For better or worse, the parliamentary debate has proceeded with an 
air of national pride. Even those opposed to MRT noted their admiration for 
the world-class work . . . .”105 One commentator believed “that this national 
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sense of pride may have swayed some votes in support of MRT.”106 Despite 
the fact that researchers in the United States have made equally important 
discoveries in this area, American scientists have not enjoyed the same 
fanfare.107 A new regulatory agency could potentially accelerate future 
research and development of germline modification technologies, if national 
attention can be brought to the issue, which has previously remained largely 
inaccessible to the general public.108 
3. Flexibility to Deal with Novel Innovations 
 Third, the HFEA was provided with the mechanisms necessary to 
deal with new innovations and novel application of existing technologies. 
For example: 
The authority of the HFEA to grant licenses is limited by the purposes 
described in the act. The decision to articulate the purposes of embryo 
usage rather than specific techniques has ensured that the act can 
incorporate novel techniques that were not envisaged when the act was 
drafted. In addition, if new techniques and applications merge that fall 
outside the HFEA’s statutory authority, the act allows parliament to 
expand the range of purposes that are placed under the HFEA’s 
authority, thereby ensuring that new purposes do not call for new 
oversight agencies and preserving the integrity of the system.109  
 Recognizing that it may be nearly impossible to keep pace with 
scientific and technological developments, Congress should consider 
providing the new independent agency in the United States with similar 
mechanisms to accommodate and adapt to contemporary developments in 
technology, information and public opinion.  
4. Clarity 
 Finally, a national and specialized agency would provide clear and 
unified regulatory guidance. Germline modification research would no 
longer need to be manipulated and interpreted to fit into the FDA’s existing 
three-category framework. The bureaucratic roadblocks that result from the 
current patchwork of oversight between the FDA, NIH, independent 
agencies and state legislation could be avoided.  
 Additional steps may be taken to further ensure clarity. For 
example, the HFEA publishes a code of practice to provide information to 
“patients, clinics, and clinicians alike” as to the “proper conduct of activities 
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carried on in pursuance of a license . . . .” 110 Thus, the HFEA is not seen as 
merely a regulatory roadblock to be overcome, but as a source of guidance.  
The support in the United Kingdom for the HFEA extends to the 
scientific and regulatory communities, which appear to have worked 
out a cooperative relationship. When a clinic cannot be licensed due to 
insufficient standards or protocols, the HFEA works with that clinic to 
ensure that it understands what is required to successfully apply for a 
license. Despite the comprehensive and highly centralized regulation, 
the United Kingdom remains committed to scientific freedom, and 
arguably has one of the most liberal embryo research policies in the 
world.”111  
 A new independent agency in the United States could similarly 
provide clarity and promote cooperation through the development of a code 
of practice designed to guide and educate patients, researchers, and 
clinicians. A more predictable system will encourage investment and ensure 
that the U.S. does not fall behind in the advancement of scientific progress. 
CONCLUSION 
 It is clear that the regulatory treatment of germline modification 
technologies in the U.S. and the U.K. have diverged significantly.112 
Questions about why these differences exist, whether they should they exist 
and what it means for some hypothetical future innovation, can no longer be 
dismissed as academic exercises. The future has arrived and “MRT 
represents but one of a growing complement of novel reproductive 
technologies, many of which will require expert regulatory adjudication.”113 
With precedent set by the international community and escalating pressure 
from within the country,114 Congress must soon decide whether and how to 
regulate MRT. Its decision may lay the foundation for how all advances in 
this field will be dealt with in the future.  
 The current patchwork of regulations and the FDA are both ill-
equipped to deal with the complex issues involved. Instead, Congress 
should consider enacting legislation to authorize the creation of a new 
regulatory agency focused specifically on the oversight of reproductive and 
genetic biotechnologies. The process will not be easy but the results may 
well be worth the effort. The bedrock formed by clear and unified 
regulatory guidance would allow for the maximization of safety and well-
being for research participants and patients, foster much needed public 
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conversation, and stimulate scientific progress in a crucial field at the 
cutting-edge of science.  
